What is the official website of MSD Switzerland ?

The official website of MSD Switzerland is http://www.msd.ch.

What is MSD Switzerland's cybersecurity risk score?

MSD Switzerland has an AI-generated cybersecurity risk score of 756 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has MSD Switzerland experienced?

According to Rankiteo, MSD Switzerland currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has MSD Switzerland been affected by any supply chain cyber incidents ?

According to Rankiteo, MSD Switzerland has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does MSD Switzerland have SOC 2 Type 1 certification ?

According to Rankiteo, MSD Switzerland is not certified under SOC 2 Type 1.

Does MSD Switzerland have SOC 2 Type 2 certification ?

According to Rankiteo, MSD Switzerland does not hold a SOC 2 Type 2 certification.

Does MSD Switzerland comply with GDPR ?

According to Rankiteo, MSD Switzerland is not listed as GDPR compliant.

Does MSD Switzerland have PCI DSS certification ?

According to Rankiteo, MSD Switzerland does not currently maintain PCI DSS compliance.

Does MSD Switzerland comply with HIPAA ?

According to Rankiteo, MSD Switzerland is not compliant with HIPAA regulations.

Does MSD Switzerland have ISO 27001 certification ?

According to Rankiteo,MSD Switzerland is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does MSD Switzerland operate in ?

MSD Switzerland operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does MSD Switzerland have ?

MSD Switzerland employs approximately 563 people worldwide.

Does MSD Switzerland own any subsidiaries ?

MSD Switzerland presently has no subsidiaries across any sectors.

How many LinkedIn followers does MSD Switzerland have ?

MSD Switzerland's official LinkedIn profile has approximately 34,355 followers.

What is the NAICS classification code for MSD Switzerland ?

MSD Switzerland is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does MSD Switzerland have a Crunchbase profile ?

No, MSD Switzerland does not have a profile on Crunchbase.

Does MSD Switzerland have a LinkedIn profile ?

Yes, MSD Switzerland maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/msdswitzerland.

How many cybersecurity incidents has MSD Switzerland experienced ?

As of August 6, 2026, Rankiteo reports that MSD Switzerland has experienced 1 cybersecurity incidents.

How many peer or competitor companies does MSD Switzerland have ?

MSD Switzerland has an estimated 5,724 peer or competitor companies worldwide.

What types of cybersecurity incidents has MSD Switzerland faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

MSD Switzerland

Boost Score +25 with badge (5 left)

756

/1000

Fair

781

/1000

Fair

MSD Switzerland Vendor Cyber Rating & Cyber Score

msd.ch

Add Your Compliance Badge

At MSD Merck Sharp & Dohme we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. MSD's success story in Switzerland began in 1963. Headquartered in Lucerne, we employ about 1,000 people at five sites in the cantons of Lucerne and Zurich. Our main therapeutic areas are oncology, infectious diseases, cardiovascular, immunology and diabetes. We also have a broad portfolio of vaccines. Switzerland holds a special place in MSD’s global footprint, serving as a key center of excellence for our research, development, manufacturing, and commercialization as well

MSD Switzerland A.I CyberSecurity Scoring

Scoring History

MSD Switzerland

MSD Switzerland CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

MSD Switzerland

Breach

9/2025

MSD060270611182...

Loading…

A.I.

MSD Switzerland Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for MSD Switzerland

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Switzerland in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for MSD Switzerland in 2026.

Incident Types MSD Switzerland vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for MSD Switzerland in 2026.

Incident History - MSD Switzerland (X = Date, Y = Severity)

Loading…

SUBSIDIARY

MSD Switzerland Subsidiaries

MSD Switzerland

Pharmaceutical Manufacturing

Website: http://www.msd.ch

Company Size: 1,001-5,000 employees

MSDPharmaceutical Manufacturing

MSD Saúde AnimalVeterinary Services

MSD Animal HealthPharmaceutical Manufacturing

MSD EgyptPharmaceutical Manufacturing

MSD LATAMPharmaceutical Manufacturing

MSD RomaniaPharmaceutical Manufacturing

MSD Animal Health UK LtdPharmaceutical Manufacturing

MSD ÖsterreichPharmaceutical Manufacturing

MSD LebanonPharmaceutical Manufacturing

MSD JordanPharmaceutical Manufacturing

MSD EspañaPharmaceutical Manufacturing

MSD NorgePharmaceutical Manufacturing

MSD SverigePharmaceutical Manufacturing

MSD SRBIJAPharmaceutical Manufacturing

MSD MagyarországPharmaceutical Manufacturing

MSD FinlandPharmaceutical Manufacturing

MSD DanmarkPharmaceutical Manufacturing

MSD PolskaPharmaceutical Manufacturing

MSD UkrainePharmaceutical Manufacturing

MSD FrancePharmaceutical Manufacturing

MSD Australia & New ZealandPharmaceutical Manufacturing

MSD Animal Health Technology LabsTechnology, Information and Internet

MSD TürkiyePharmaceutical Manufacturing

MSD SlovenskoPharmaceutical Manufacturing

MSD GCCPharmaceutical Manufacturing

MSD South AfricaPharmaceutical Manufacturing

MSD NetherlandsPharmaceutical Manufacturing

MSD ItaliaPharmaceutical Manufacturing

MSD Czech RepublicPharmaceutical Manufacturing

MSD BelgiumPharmaceutical Manufacturing

MSD in the UKPharmaceutical Manufacturing

MSD PortugalPharmaceutical Manufacturing

MSD DeutschlandPharmaceutical Manufacturing

MSD GreecePharmaceutical Manufacturing

Loading…

MSD Switzerland Similar Companies

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Torrent Pharmaceuticals Ltd

cb torrentpharma.com

Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (CNS), Gastro-intestinal (GI), Vitamins Minerals Nutritionals (VMN) and Cosmo-Dermatology. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments. Torrent has 8 manufacturing facilities , of which 5 are USFDA approved. With R&D as the backbone for its growth in domestic & overseas market, it has invested significantly in R&D capabilities with state-of-the-art R&D infrastructure employing around 800 scientists. The acquisition of Elder Pharma's Indian branded business in 2013, Dermaceuticals business of Zyg Pharma in 2015, API plant of Glochem Industries in 2016, Women healthcare brands from Novartis and Unichem's Indian branded business along with its Sikkim Plant in 2017 strengthened Torrent Pharma's position in the Indian Pharma market. Torrent Pharma started international acquisitions in 2005 with entry into the German market. Today, the Company has presence in more than 50 countries and is ranked No. 1 among the Indian pharma Companies in Brazil and Germany. Torrent Pharma is committed towards “not just healthcare but lifecare.”

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

MENARINI Group

menarini.com

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

MSD

msd.com

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

Loading…

NEWS

MSD Switzerland CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

November 18, 2001 08:00 AM

AUDIT : the Alcohol Use Disorders Identification Test : guidelines for use in primary health care

This manual introduces the AUDIT, the Alcohol Use Disorders Identification Test, and describes how to use it to identify persons with hazardous and harmful...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-67867

SUMMARY

Buffer Overflow vulnerability in Systerel S2OPC 1.7.3 allows a remote attacker to cause a denial of service via the Alarm/Conditions wrapper when processing PublishResponse EventNotificationList data

Published

Date2026-08-05

Updated

Date2026-08-05

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-67866

SUMMARY

Buffer Overflow vulnerability in Systerel S2OPC 1.7.3 allows a remote attacker to cause a denial of service via the LockedStaMac_ProcessMsg_DeleteMonitoredItemsResponse and SOPC_StaMac_NewDeleteMonitoredItems in the client wrapper DeleteMonitoredItems path

Published

Date2026-08-05

Updated

Date2026-08-05

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-67863

SUMMARY

In open62541 1.5.5, a server-side use-after-free exists in the local MonitoredItem callback path. The issue occurs when UA_Subscription_localPublish continues to use the current UA_Notification after a callback invokes UA_Server_deleteMonitoredItem for the current local MonitoredItem. This allows a remote attacker to cause a denial of service.

Published

Date2026-08-05

Updated

Date2026-08-05

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-19026

SUMMARY

H5Z__filter_nbit in H5Znbit.c in HDF5 through 2.3.0 dereferences cd_values[0] through cd_values[4] without validating that cd_values is non-NULL or that cd_nelmts is at least 5, the fixed size of the filter's header. This allows attackers to cause a denial of service via a crafted HDF5 file that stores the N-Bit filter pipeline message with zero client-data values, opened and read via H5Dread, e.g. by the h5ls or h5repack tools.

Published

Date2026-08-05

Updated

Date2026-08-05

RISK INFORMATION (Score: )

cvss4

Base Score: 6.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-19025

SUMMARY

H5O__layout_decode in H5Olayout.c in HDF5 through 2.3.0 does not validate that a chunked dataset's stored chunk-layout dimensionality matches its dataspace rank when an existing dataset is opened, whereas this check is performed only at dataset-creation time. This allows attackers to cause a denial of service (divide-by-zero and application crash in H5S__hyper_iter_get_seq_list in src/H5Shyper.c) via a crafted HDF5 file with mismatched chunk/dataspace ranks that is opened and read via H5Dopen2 and H5Dread, e.g. by the h5repack tool.

Published

Date2026-08-05

Updated

Date2026-08-05

RISK INFORMATION (Score: )

cvss4

Base Score: 6.8

Complexity: LOW

CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:P/VC:N/VI:N/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

https://github.com/HDFGroup/hdf5/issues/6491

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…